Imugene

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Bigtincan Holdings Limited

BTH

BigTinCan Holdings Ltd. is a global software company, which engages in providing AI-powered sales enablement automation platform. The company is headquartered in Sydney, New South Wales. The company went IPO on 2017-03-24. The firm provides an artificial intelligence (AI)-powered sales enablement automation platform. The Company’s principal activity is the provision of an integrated, online platform, Bigtincan Hub, a collaborative and secure solution that automatically delivers the relevant content to the right users directly, across any device and any network. The company provides software as a service (SaaS) application platform, creating a comprehensive solution that offers customers tools for sales content management (Bigtincan Content Hub), sales readiness (Learning Hub) and sales engagement (Engagement Hub), which is engaged in working together to create its Intelligent Enablement Platform (IEP). The firm operates globally with users in over 50 countries and with a solution localized into approximately 40 languages. Its products are used by various companies across the world, with over 2000 deployments and more than one million users.

Alcidion Group Limited

ALC

Alcidion Group Ltd. engages in the development and provision of healthcare software products marketed under the Miya, Patientrack, Smartpage and ExtraMed brands. The company is headquartered in Melbourne, Victoria. The company went IPO on 2011-06-24. The firm's principal activities include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, systems integration, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its product, Miya Precision, is a smart clinical solution based on a FHIR-event platform that facilitates multiple clinical and operational applications. The firm's other products include Smartpage, Patientrack, and Silverlink PCS. Smartpage is an advanced smartphone and Web-based system for hospital communication and task management, addressing the requirements of both clinical and non-clinical users.

Accent Group Limited

AX1

Accent Group Ltd. operates as an investment holding company, which engages in the retail of performance and lifestyle footwear. The company is headquartered in Richmond, Victoria. The company went IPO on 2004-07-07. The firm operates approximately 786 stores and approximately 35 Websites across different retail banners, and distribution rights for 17 international brands across Australia and New Zealand. The firm's geographical segments include Australia and New Zealand. The Company’s banners and brands include The Athlete’s Foot (TAF), Platypus Shoes, Hype DC, Skechers, Merrell, CAT, Vans, Dr. Martens, Saucony, Timberland, HOKA, Superga, Kappa, Palladium, Supra, Subtype, The Trybe, Stylerunner, Glue Store, Autry, and UGG. Its subsidiaries include The Athlete's Foot Australia Pty Ltd, RCG Brands Pty Ltd, RCG Retail Pty Ltd, TAF eStore Pty Ltd, Accent Store Development Pty Ltd, Hype DC Pty Ltd, Subtype Pty Ltd, Accent Active (NZ) Limited, TAF Hornsby Pty Ltd, and Accent Lifestyle (NZ) Limited.

Arafura Rare Earths Ltd

ARU

Arafura Rare Earths Ltd. engages in the exploration and development of mineral resource properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-11-05. The firm produces rare earth products from the Nolans Project. The Nolans Project consists of a mine, process plant, including beneficiation, extraction and separation plants, and related infrastructure to be constructed and located at the Nolans site, approximately 135 kilometers north of Alice Springs in Australia's Northern Territory. Its rare earth products are Neodymium-Praseodymium (NdPr) oxide, and Mixed middle-heavy rare earths (SEG/HRE) oxide. NdPr oxide is the Company's flagship product, which is used by magnet and magnet alloy customers. The Company’s primary products from the Nolans project are rare earths, which are used in catalytic converters in automobiles, consumer electronics, energy efficiency lighting, optics, alloys, advanced ceramics and permanent magnets that enable e-mobility and renewable energy applications.